Solventum SEC filings, summarized
We read every Solventum 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track SOLV in your inbox
Add Solventum to your watchlist — free, every morning.
Recent filings
Solventum raises 2026 outlook after Q2 sales and adjusted EPS growth
Solventum reported second-quarter 2026 sales of $2.209 billion for the period ended June 30, up 2.2% year over year, while organic sales rose 9.5%; adjusted…
Solventum Plans to Separate $1.4 Billion Health Information Systems Business
Solventum announced on August 5, 2026, that it intends to pursue a separation of its Health Information Systems business, which generated $1.4 billion in…
Solventum Plans to Separate $1.4 Billion Health Information Systems Business
Solventum said on August 5, 2026, that it intends to pursue a separation of its Health Information Systems business, which generated $1.4 billion in sales…
Solventum filed an 8‑K (Item 9.01) on Mar 24, 2026 submitting Exhibit 104 — an Interactive Inline XBRL…
Solventum filed an 8‑K (Item 9.01) on Mar 24, 2026 submitting Exhibit 104 — an Interactive Inline XBRL cover page. Filed and signed by Wayde McMillan, EVP &…
On Mar 20, 2026 Mary Wilcox informed Solventum Corporation she intends to retire and resign as Chief…
On Mar 20, 2026 Mary Wilcox informed Solventum Corporation she intends to retire and resign as Chief Accounting Officer, effective upon appointment of her…
Solventum filed an 8‑K (Item 9.01) on Feb 26, 2026 furnishing Exhibit 99.1 — a press release dated…
Solventum filed an 8‑K (Item 9.01) on Feb 26, 2026 furnishing Exhibit 99.1 — a press release dated 2/26/2026 — and Exhibit 104 (Interactive XBRL cover…
Solventum Corp issued a press release on Feb 26, 2026 reporting Q4 2025 results and introducing full‑year…
Solventum Corp issued a press release on Feb 26, 2026 reporting Q4 2025 results and introducing full‑year 2026 financial guidance. Investors should review…